Please ensure Javascript is enabled for purposes of website accessibility

Meds Without Passports

By Kris Eddy – Updated Apr 6, 2017 at 12:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Senate defeats one amendment to allow Americans to import cheaper prescription medicines.

Bernie Sanders, Vermont's junior senator with a penchant for deeming things "outrageous," proudly relates on his website how he took constituents across the border to (illegally) buy cheaper prescription drugs in Canada.

This week, the Associated Press reports, the Senate rejected a plan to let Americans import low-cost prescriptions from abroad. "White House officials have denied accusations ... that the administration was opposing importation as a way of retaining the drug industry's support for Obama's health care overhaul legislation, the president's top domestic priority," reports the AP.

How much of a role do you think the powerful drug and health-care lobbies should have? Among its top 10 spenders in 2009, the Center for Responsive Politics lists AARP at No. 8, Pfizer at No. 6, Blue Cross/Blue Shield at No. 5, and Pharmaceutical Research & Manufacturers of America -- whose members include such heavy-hitters as Abbott Labs (NYSE:ABT), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), and Merck (NYSE:MRK) -- at No. 3.

Sound off in the comments box below. For each post, the Fool will donate $0.10 to the Thurgood Marshall Academy in Washington, D.C., in furtherance of financial literacy.

Fool online editor Kris Eddy owns no shares of any stocks mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co. Stock Quote
Merck & Co.
MRK
$92.94 (-0.34%) $0.32
Pfizer Stock Quote
Pfizer
PFE
$42.91 (-0.46%) $0.20
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$95.21 (-2.96%) $-2.90
Amgen Stock Quote
Amgen
AMGN
$247.45 (-0.30%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
340%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.